Astellas Pharma Overview

  • Founded
  • 1923
Founded
  • Status
  • Public
  • Employees
  • 15,883
Employees
  • Stock Symbol
  • 4503
Stock Symbol
  • Investments
  • 26
  • Share Price
  • $16.29
  • (As of Thursday Closing)

Astellas Pharma General Information

Description

Astellas Pharma Inc is a drug manufacturing company that sells pharmaceutical products across the globe. The vast majority of the company's revenue is derived from Japanese markets, followed by the Americas. Royalty income makes up a small percentage of Astellas' overall sales. Its largest therapeutic area by sales composition is oncology, followed by urology and transplantation. The company uses mergers and acquisitions as part of its long-term growth strategy. Astellas enters into strategic partnerships and licensing agreements to strengthen its commercialization platforms.

Contact Information

Formerly Known As
Fujisawa Pharmaceutica, Yamanouchi Pharmaceutical
Ownership Status
Publicly Held
Financing Status
Corporate Backed or Acquired
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Drug Discovery
Stock Exchange
TKS
Primary Office
  • 2-5-1, Nihonbashi-Honcho
  • Chuo-ku
  • Tokyo, 103-8411
  • Japan
+81 00-0000-0000
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Astellas Pharma Stock Performance

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$16.29 $16.46 $13.02 - $18.43 $30.3B 1.86B 5.22M $0.96

Astellas Pharma Financials Summary

In Thousands,
USD
TTM 30-Jun-2020 FY 2020 31-Mar-2020 FY 2019 31-Mar-2019 FY 2018 31-Mar-2018
EV 32,426,090 27,636,821 25,970,880 27,115,502
Revenue 11,775,458 11,959,632 11,782,368 11,730,093
EBITDA 2,728,298 2,853,622 2,772,259 2,508,917
Net Income 1,731,689 1,796,561 2,004,679 1,485,562
Total Assets 20,966,687 21,449,934 17,114,508 17,485,709
Total Debt 4,125,764 4,394,981 604,422 536,191
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Astellas Pharma Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Astellas Pharma‘s full profile, request access.

Request a free trial

Astellas Pharma Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Astellas Pharma Inc is a drug manufacturing company that sells pharmaceutical products across the globe. The vast majori
Pharmaceuticals
Tokyo, Japan
15,883 As of 2020
000000000000

000000 0

illum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa
000000000000000
Tokyo, Japan
00000 As of 0000
00000000

0000 000

mpor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation
000000000000000
Petach Tikva, Israel
00000 As of 0000
00000
00000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Astellas Pharma Competitors (39)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Takeda Pharmaceutical Company Corporation Tokyo, Japan 00000 00000000
0000 0000000000000 Corporate Backed or Acquired Petach Tikva, Israel 00000 00000 00000000000 00000
000 000000 Corporate Backed or Acquired Monheim, Germany 0000 000000&0
00000000 Corporation Basel, Switzerland 000000 000000000000
000000000000000 Corporation Brentford, United Kingdom 00000 00000000000
You’re viewing 5 of 39 competitors. Get the full list »

Astellas Pharma Executive Team (24)

Name Title Board Seat Contact Info
Kenji Yasukawa Ph.D Chief Executive Officer & President
Masao Yoshida Chief Executive Officer, Astellas Pharma Europe
Seigo Kashi President
Chikashi Takeda Chief Financial Officer
Naoki Okamura Vice President, Corporate Development & Chief Strategy Officer
You’re viewing 5 of 24 executive team members. Get the full list »

Astellas Pharma Board Members (1)

Name Representing Role Since
00000000 00000000 Astellas Pharma Chairman & Representative Director 000 0000
To view Astellas Pharma’s complete board members history, request access »

Astellas Pharma Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Astellas Pharma Investments & Acquisitions (26)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000 000000000000 21-Apr-2020 000000000000000000 000.00 Biotechnology 00000 00000000 00.0
00000000 000000000 15-Jan-2020 000000000000000000 00.000 Biotechnology 00000 00000000 00.0
000000 00000000000 26-Dec-2019 000000000000000000 00000 Biotechnology 00000 00000000 00.0
000000 0000000000 28-Oct-2019 00000 0000 Enterprise Systems (Healthcare)
LabCentral 04-Oct-2019 Corporate 0000 Other Commercial Services
You’re viewing 5 of 26 investments and acquisitions. Get the full list »

Astellas Pharma Subsidiaries (11)

Company Name Industry Location Founded
Xyphos Biosciences Biotechnology South San Francisco, CA 2017
0000000 0000000000 Biotechnology Cambridge, MA 0000
000000000 00000 Biotechnology Seattle, WA 0000
00000 000000000000 Biotechnology Cambridge, United Kingdom 0000
00000000 000000000 Biotechnology San Francisco, CA 0000
You’re viewing 5 of 11 subsidiaries. Get the full list »

Astellas Pharma Exits (6)

Company Name Exit Date Exit Type Exit Size Status Buyers
000000 000 02-Jun-2015 00000 00000 00 000.00 Completed
  • 5 buyers
000000 000 29-May-2015 00000 0000000 00000 Completed
  • 2 buyers
00000 00000000 000 01-Oct-2013 00000 0000000 Completed
  • 2 buyers
0000000 (000000000 22-Jun-2009 000000000 00000 00 0000 Completed
  • 00000000 000000
FibroGen 10-Jan-2007 Later Stage VC 0000 Completed
  • 2 buyers
You’re viewing 5 of 6 exits. Get the full list »